Page last updated: 2024-09-05

erlotinib hydrochloride and Prostatic Neoplasms, Castration-Resistant

erlotinib hydrochloride has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Biordi, L; Festuccia, C; Ficorella, C; Gravina, GL; Jannini, EA; Marampon, F; Motta, M; Piccolella, M; Tombolini, V	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Prostatic Neoplasms, Castration-Resistant

Article	Year
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. The Prostate, 2011, Oct-01, Volume: 71, Issue:14 Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays	2011

Article

Year

Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.

The Prostate, 2011, Oct-01, Volume: 71, Issue:14

Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Male; Mice, Nude; Morpholines; Nitriles; Orchiectomy; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinazolines; Tosyl Compounds; Xenograft Model Antitumor Assays

2011